Neurocrine Biosciences, Inc. $NBIX Shares Sold by Vanguard Group Inc.

Vanguard Group Inc. lessened its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 1.0% in the 3rd quarter, Holdings Channel.com reports. The firm owned 9,706,559 shares of the company’s stock after selling 100,507 shares during the quarter. Vanguard Group Inc. owned about 0.10% of Neurocrine Biosciences worth $1,362,607,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Golden State Wealth Management LLC grew its holdings in Neurocrine Biosciences by 120.5% in the third quarter. Golden State Wealth Management LLC now owns 183 shares of the company’s stock valued at $26,000 after purchasing an additional 100 shares during the period. Eastern Bank acquired a new position in shares of Neurocrine Biosciences during the 3rd quarter worth approximately $27,000. Geneos Wealth Management Inc. lifted its position in shares of Neurocrine Biosciences by 143.6% during the 1st quarter. Geneos Wealth Management Inc. now owns 229 shares of the company’s stock valued at $25,000 after buying an additional 135 shares in the last quarter. Quent Capital LLC acquired a new stake in Neurocrine Biosciences in the 3rd quarter valued at $32,000. Finally, MAI Capital Management increased its holdings in Neurocrine Biosciences by 101.2% in the 2nd quarter. MAI Capital Management now owns 328 shares of the company’s stock worth $41,000 after acquiring an additional 165 shares in the last quarter. Hedge funds and other institutional investors own 92.59% of the company’s stock.

Neurocrine Biosciences Trading Down 1.1%

NBIX opened at $128.63 on Friday. Neurocrine Biosciences, Inc. has a twelve month low of $84.23 and a twelve month high of $160.18. The firm has a market capitalization of $12.91 billion, a PE ratio of 27.60, a PEG ratio of 0.68 and a beta of 0.31. The firm’s 50-day moving average price is $137.46 and its 200 day moving average price is $140.28.

Neurocrine Biosciences (NASDAQ:NBIX) last released its earnings results on Wednesday, February 11th. The company reported $1.88 earnings per share for the quarter, missing analysts’ consensus estimates of $2.36 by ($0.48). The business had revenue of $805.50 million during the quarter, compared to analysts’ expectations of $804.21 million. Neurocrine Biosciences had a return on equity of 16.48% and a net margin of 16.73%.The company’s revenue for the quarter was up 28.3% compared to the same quarter last year. During the same period last year, the business earned $1.69 earnings per share. As a group, analysts predict that Neurocrine Biosciences, Inc. will post 4.28 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Neurocrine Biosciences news, CEO Kyle Gano sold 36,400 shares of the business’s stock in a transaction on Friday, January 16th. The stock was sold at an average price of $132.70, for a total transaction of $4,830,280.00. Following the transaction, the chief executive officer owned 140,407 shares of the company’s stock, valued at approximately $18,632,008.90. The trade was a 20.59% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Darin Lippoldt sold 4,376 shares of the company’s stock in a transaction on Monday, December 8th. The shares were sold at an average price of $159.65, for a total value of $698,628.40. Following the completion of the sale, the insider owned 43,405 shares of the company’s stock, valued at approximately $6,929,608.25. The trade was a 9.16% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 61,966 shares of company stock worth $8,625,166. 4.80% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several equities analysts have issued reports on the stock. Wall Street Zen downgraded shares of Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a report on Monday, February 16th. TD Cowen boosted their target price on shares of Neurocrine Biosciences from $175.00 to $200.00 and gave the stock a “buy” rating in a research note on Friday, December 5th. BMO Capital Markets decreased their price target on shares of Neurocrine Biosciences from $147.00 to $140.00 and set a “market perform” rating on the stock in a research note on Thursday, February 12th. Royal Bank Of Canada lowered their price objective on Neurocrine Biosciences from $180.00 to $177.00 and set an “outperform” rating on the stock in a report on Thursday, February 12th. Finally, Truist Financial cut their price objective on Neurocrine Biosciences from $169.00 to $140.00 and set a “buy” rating for the company in a research note on Tuesday. Sixteen investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Neurocrine Biosciences presently has an average rating of “Moderate Buy” and a consensus target price of $175.84.

Neurocrine Biosciences Profile

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.